Somatostatin receptor (SSTR) scintigraphy is currently used as one standard imaging modality in neuroendocrine tumors (NETs). However, future optimization of NET imaging may be achieved with positron emission tomography based methods utilizing more sensitive and specific tracers in combination with computed tomography or magnetic resonance imaging. Here we established an orthotopic mouse model that reflects relevant aspects of human pancreatic NETs such as SSTR expression, dense vascularization and metastatic disease. This model was then utilized to test the feasibility of combined magnetic resonance imaging and animal positron emission tomography. Orthotopic implantation of amphicrine, SSTR-positive pancreatic AR42J cells resulted in rapidly growing tumors, with concomitant metastatic spread into abdominal lymph nodes and peritoneal cavity. Primary tumors as well as their metastases expressed the neuroendocrine markers chromogranin A and synaptophysin. For imaging experiments, the SSTR ligands 68Ga-DOTATOC or 68Ga-DOTANOC were injected intravenously, and animals were subsequently examined in an animal positron emission tomography scanner and a clinical 3T (tesla) magnetic resonance imager. All animals showed radionuclide accumulation in the primary tumor. Definite anatomical correlation was achieved using digital image fusion of the positron emission tomography and magnetic resonance imaging data. 68Ga-DOTANOC strongly accumulated in the tumor tissue (mean 6.6-fold vs. control tissues) when compared to 68Ga-DOTATOC, which showed a higher renal clearance. In good agreement with the biodistribution data, the kidney-to-tumor ratio was higher for 68Ga-DOTATOC (2.43-fold vs. 1.75-fold). Consequently, 68Ga-DOTANOC achieved better signal enhancement in the primary tumor and allowed for detection of metastatic lesions. In summary, we established a novel orthotopic pancreatic SSTR-positive tumor model and used this model to provide proof of principle for the diagnostic combination of SSTR-based molecular imaging and magnetic resonance imaging. Specifically, the animal model allowed the comparative evaluation of 68Ga-DOTANOC and 68Ga-DOTATOC, with 68Ga-DOTANOC providing better tumor-specific accumulation and renal activity. We conclude that this animal model will be of innovative value for further investigation in the imaging of NETs.

Keywords:
Neuroendocrine tumors, Imaging, neurondocrine tumors, Animal positron emission tomography, Animal model, pancreatic neuroendocrine tumors, Somatostatin receptor
1.
Plockinger U, Rindi U, Arnold R, Eriksson B, Krenning E, de Herder W, Goede A, Caplin M, Oberg K, Reubi J, Nilsson O, Fave GD, Ruszniewski P, Ahlman H, Wiedenmann B: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394–424.
2.
Reubi J: Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004;80 (Suppl 1):51–56.
3.
Newman J, Lluis F, Thompson J, Greely GH Jr, Rayford P, Townsend CT Jr: Somatostatin. Gastrointestinal Endocrinology. New York, McGraw-Hill, 1987, pp 286–299.
4.
Froidevaux S, Eberle A, Christe M, Sumanovski L, Heppeler A, Schmitt J, Eisenwiener K, Beglinger C, Mäcke H: Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002;98:930–937.
5.
Hejna M, Schmidinger M, Raderer M: The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002;13:653–668.
6.
Rambaldi P, Cuccurullo V, Briganti V, Mansi L: The present and future role of 111In pentetreotide in the PET era. Q J Nucl Med Mol Imaging 2005;49:225–235.
7.
Hofmann M, Mäcke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H: Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–1757.
8.
Kowalski J, Henze M, Schuhmacher J, Mäcke H, Hofmann M, Haberkorn U: Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42–48.
9.
Wild D, Mäcke H, Waser B, Reubi J, Ginj M, Rasch H, Müller-Brand J, Hofmann M: 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005;32:724.
10.
Rosewicz S, Vogt D, Harth N, Grund C, Franke W, Ruppert S, Schweitzer E, Riecken E, Wiedenmann B: An amphicrine pancreatic cell line: AR42J cells combine exocrine and neuroendocrine properties. Eur J Cell Biol 1992;59:80–91.
11.
Eisenwiener K, Prata M, Buschmann I, Zhang H, Santos A, Wenger S, Reubi J, Mäcke H: NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002;13:530–541.
12.
Henriksen G, Schottelius M, Poethko T, Hauser A, Wolf I, Schwaiger M, Wester H: Proof of principle for the use of 11C-labelled peptides in tumour diagnosis with PET. Eur J Nucl Med Mol Imaging 2004;31:1653–1657.
13.
Ugur O, Kothari P, Finn R, Zanzonico P, Ruan S, Guenther I, Maecke H, Larson S: Ga-66 labeled somatostatin analogue DOTA-D Phe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002;29:147–157.
14.
Schottelius M, Poethko T, Herz M, Reubi J, Kessler H, Schwaiger M, Wester H: First 18F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004;10:3593–3606.
15.
Bernhardt P, Kolby L, Johanson V, Benjegard S, Nilsson O, Ahlman H, Forssell-Aronsson E: Biokinetics of 111In-DTPA-D-Phe1-octreotide in nude mice transplanted with a human carcinoid tumor. Nucl Med Biol 2001;28:67–73.
16.
Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W, Wiedenmann B, Grotzinger C: Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 2001;19:327–331.
17.
Manzotti C, Audisio R, Pratesi G: Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis 1993;11:5–14.
18.
Talmadge J, Singh R, Fidler I, Raz A: Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170:793–804.
19.
Pietrzyk U, Herholz K, Fink G: An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994;35:2011–2018.
20.
Alves F, Contaq S, Missbach M, Kaspareit J, Nebendahl K, Borchers U, Heidrich B, Streich R, Hiddemann W: An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade. Pancreas 2001;23:227–235.
21.
Hofsli E, Thommesen L, Norsett K, Falkmer S, Syversen U, Sandvik A, Laegreid A: Expression of chromogranin A and somatostatin receptors in pancreatic AR42J cells. Mol Cell Endocrinol 2002;194:165–173.
22.
Plockinger U, Wiedenmann B: Endocrine tumours of the gastrointestinal tract. Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:553–576.
23.
Kerbel R: What is the optimal rodent model for anti-tumor drug testing? Cancer Metastasis Rev 1998–1999;17:301–304.
24.
Cespedes M, Casanova I, Parreno M, Mangues R: Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006;8:318–329.
25.
Nobels F, Kwekkeboom D, Bouillon R, Lamberts S: Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998;28:431–440.
26.
Wiedenmann B: Synaptophysin. A widespread constituent of small neuroendocrine vesicles and a new tool in tumor diagnosis. Acta Oncol 1991;30:435–440.
27.
Grotzinger C: Tumour biology of gastroenteropancreatic neuroendocrine tumours. Neuroendocrinology 2004;80:8–11.
28.
Townsend C, Ishizuka J, Thompson JC: Studies of growth regulation in a neuroendocrine cell line. Acta Oncol 1993;32:125–130.
29.
Kimura N, Funakoshi A, Aunis D, Tateishi K, Miura W, Nagura H: Immunohistochemical localization of chromostatin and pancreastatin, chromogranin A-derived bioactive peptides, in normal and neoplastic neuroendocrine tissues. Endocr Pathol 1995;6:35–43.
30.
Taylor J, Theveniau M, Bashirzadeh R, Reisine T, Eden P: Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 1994;15:1229–1236.
31.
Franzius C, Hotfilder M, Poremba C, Hermann S, Schäfers K, Gabbert H, Jürgens H, Schober O, Schäfers M, Vormoor J: Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model. Eur J Nucl Med Mol Imaging 2006;33:1432–1441.
32.
Deroose C, De A, Loening A, Chow P, Ray P, Chatziioannou A, Gambhir SS: Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. J Nucl Med 2007;48:295–303.
33.
Koukouraki S, Strauss L, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A: Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115–1122.
34.
Robinson M, Doss M, Shaller C, Narayanan D, Marks J, Adler L, Trotter DG, Adams G: Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005;65:1471–1478.
35.
Biddlecombe G, Rogers B, de Visser M, Parry J, de Jong M, Erion J, Lewis J: Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1–14). Bioconjug Chem 2007;18:724–730.
36.
Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu J, Xing L, Chen X: 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006;47:492–501.
37.
Reubi J, Kvol L, Krenning E, Lamberts S: Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990;39:78–81.
38.
Yamada Y, Post S, Wang W, Tager W, Bell G, Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 1992;89:251–255.
39.
Reubi J, Schaer J, Markwalder R, Waser B, Horisberger U, Laissue J: Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997;70:471–479.
40.
Reubi J, Schär J, Waser B, Wenger S, Heppeler A, Schmitt J, Mäcke H: Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–282.
41.
Savelli G, Lucignani G, Seregni E, Marchiano A, Serafini G, Aliberti G, Villano C, Maccauro M, Bombardieri E: Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun 2004;25:445–449.
42.
Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, van Graafeiland B, Monetti N, Bombardieri E: Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25:1396–1403.
43.
Wild D, Schmitt J, Ginj M, Mäcke H, Bernard B, Krenning E, de Jong M, Wenger S, Reubi J: DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338–1347.
44.
Hansen L, Marzilli L, Eshima D: Evaluation of technetium-99m-triamide-mercaptide complexes designed to identify properties favoring renal tubular transport. J Nucl Med 1994;35:1198–1205.
45.
de Jong M, Breeman W, Valkema R, Bernard B, Krenning E: Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):13S–17S.
46.
Forrer F, Uusijärvi H, Storch D, Maecke H, Mueller-Brand J: Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005;46:1310–1316.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.